Life Sciences Technology Traditional
 
  Life Sciences Portfolio
Exited Companies
Current Portfolio

Exited Companies
  Cita NeuroPharmaceuticals Inc.
Acquired by Vernalis PLC in December 2005, Cita developed and commercialized small molecule drug candidates for neurological diseases and disorders.

Kadmus Pharmaceutical Ltd.
Kadmus develops therapeutics for pain, obesity and other central nervous system disorders. In May 2007, its main program was purchased by Dutch biotech firm, Organon BioSciences N.V.

LymphoSign Inc.
LymphoSign developed a small molecule drug candidate, which directly targets cancer cells for leukemia and other forms of blood-related cancers. In August 2007, LymphoSign was sold to Aegera Therapeutics Inc.
     
Current Portfolio Investee Companies

  ActivBiotics Canada Inc.
ActivBiotics is a late clinical-stage biotechnology company that discovers, develops and commercializes therapies for the treatment of inflammatory diseases and bacterial infections.

Adherex Technologies Inc.
Adherex is a clinical-stage company dedicated to developing new therapies for cancer and cancer side effects.

  Aegera Oncology Inc.
Aegera is a clinical-stage biotechnology company that develops drugs to treat cancer and other serious diseases including pain related to diabetes and other injuries. 

Axela Biosensors Inc.
Axela develops technologies for protein detection, characterization and monitoring for use in life science, health and clinical research.

  Cytochroma Canada Inc.
Cytochroma is a clinical-stage biotechnology firm, which develops proprietary products to treat and prevent the clinical consequences of vitamin D deficiency, with a specific focus on chronic kidney disease and related complications.

Interface Biologics Inc.
Interface develops unique biomaterials for the coating and manufacturing of a new generation of medical devices to improve compatibility, efficacy and safety.

  Targanta Therapeutics (Ontario) Inc.
Targanta Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing and commercializing novel antibacterial agents to address life-threatening infections for the hospital market.

  Trillium Therapeutics Inc.
Trillium develops therapies that restore balance to the immune system for many conditions such as autoimmune and inflammatory disorders as well as cancer.

VisualSonics Inc.
VisualSonics is the world’s leading developer of high-resolution, ultrasound based in-vivo micro-imaging systems, specifically designed for non-invasive pre-clinical research.

Xceed Molecular Inc.
Xceed is a molecular diagnostics company, providing scientists and clinical researchers with innovative systems to translate novel multiplex gene expression tests into routine clinical practice.

  Zelos Therapeutics Inc.
Zelos is a biopharmaceutical company developing novel therapies for patients suffering from conditions responsive to parathyroid hormone-based therapeutics. The Company is in late-stage clinical development with Ostabolin-C™, a parathyroid hormone analogue designed to improve upon the safety and efficacy of current therapies in the large and rapidly growing osteoporosis market.

Z-Tech (Canada) Inc.
Committed to improving breast cancer survivor rates, Z-Tech develops and markets revolutionary radiation-free breast screening products.